Information about making a PBAC submission for Ravulizumab
Dear MG Community,
The Myasthenia Alliance Australia (MAA) is sharing the attached information with you about the current opportunity to make a personal submission to the Pharmaceutical Benefits Advisory Committee (PBAC) about a new treatment called Ravulizumab. The deadline for submissions is 31 January 2024 and we will share more information in the new year.
May we also take this opportunity to wish you a safe, happy, and relaxing festive season and we look forward to continue supporting you and being in touch in 2024.
The Consumer Submission can be downloaded as a PDF from here:
The Consumer Submission can be downloaded as a Word document from here:
The MAA Board